Skip to main content

Table 6 Prophylactic treatments against pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients[4].

From: Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison

Treatment Comparison

Mixed Treatment Comparison

Adjusted Indirect Comparison

 

Odds Ratio

95% Credible Interval

Odds Ratio

95% Confidence Interval

AP vs. TMP-SMX

2.68

(1.90, 3.81)

3.19

(2.02, 5.03)

D vs. TMP-SMX

1.38

(0.94, 2.04)

0.92

(0.58, 1.46)

D/P vs. TMP-SMX

3.02

(1.92, 4.79)

3.22

(1.70, 6.10)

D vs. AP

0.52

(0.34, 0.78)

0.90

(0.53, 1.52)

D/P vs. AP

1.13

(0.71, 1.80)

0.86

(0.47, 1.57)

D/P vs. D

2.19

(1.26, 3.82)

3.5

(1.59, 7.69)***

  1. Bolded text denotes head-to-head meta-analysis evaluations. * Mixed treatment method identifies a significant effect, adjusted indirect comparison does not, adjusted indirect comparison identifies significant effect, mixed treatment comparison does not. ** Direction of effect differs between approaches, ***Important effect size differences.
Back to article page

Trials

ISSN: 1745-6215